Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells.
Evodiamine, an indole alkaloid derived from Evodia rutaecarpa, exhibits pharmacological activities including vasodilatation, analgesia, anti-cardiovascular disease, anti-Alzheimer's disease, anti-inflammation, and anti-tumor activity.



This study analyzes the anti-tumor effects of evodiamine on cellular growth, tumorigenesis, cell cycle and apoptosis induction of human urothelial cell carcinoma (UCC) cells.



The present study showed that evodiamine significantly inhibited the proliferation of UCC cells in a dose- and time-dependent manner. Also, evodiamine suppressed the tumorigenesis of UCC cells in vitro. Moreover, evodiamine caused G2/M cell-cycle arrest and induced caspase-dependent apoptosis in UCC cells. Finally, we demonstrated that evodiamine exhibits better cytotoxic than 5-fluorouracil, a clinical chemotherapeutic drug, for UCC cells.



Evodiamine induces growth inhibition, tumorigenesis suppression, cell-cycle arrest, and apoptosis induction in human UCC cells. Therefore, this agent displays a therapeutic potential for treating human UCC cells and is worthy for further investigation.
Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C.|Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan, R.O.C.
Chung-Sheng
CS
Shi
Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C.
Jhy-Ming
JM
Li
Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C.|Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan, R.O.C.
Chih-Chien
CC
Chin
Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C.|Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan, R.O.C.
Yi-Hung
YH
Kuo
Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan, R.O.C. yingray.lee@gmail.com chrishyc@gmail.com.
Ying-Ray
YR
Lee
Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C. yingray.lee@gmail.com chrishyc@gmail.com.|Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan, R.O.C.
Yun-Ching
YC
Huang
D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry*; D017209:Apoptosis; D063646:Carcinogenesis / Q000187:drug effects*; D002277:Carcinoma / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects; D049109:Cell Proliferation; D004354:Drug Screening Assays, Antitumor; D016650:Fluorescein-5-isothiocyanate; D005472:Fluorouracil / Q000737:chemistry; D006801:Humans; D009154:Mutation; D010936:Plant Extracts; D011799:Quinazolines / Q000737:chemistry*; D015398:Signal Transduction; D001749:Urinary Bladder Neoplasms / Q000473:pathology*; D019459:Urothelium / Q000473:pathology*
D000972:Antineoplastic Agents, Phytogenic; D010936:Plant Extracts; D011799:Quinazolines; C049639:evodiamine; D016650:Fluorescein-5-isothiocyanate; D005472:Fluorouracil
Evodiamine; apoptosis; cell-cycle arrest; urothelial cell carcinoma